Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18.91	34.1	32.4	12.59	36.83
Short-Term Investments	169.35	73.53	50.57	107.92	-
Cash & Short-Term Investments	188.26	107.62	82.97	120.51	36.83
Cash Growth	74.93%	29.71%	-31.15%	227.21%	-18.16%
Other Current Assets	3.4	1.81	4.58	2.11	1.13
Total Current Assets	191.66	109.43	87.55	122.62	37.96
Net Property, Plant & Equipment	0.86	1.23	1.56	0.19	0.18
Other Long-Term Assets	0.93	0.24	0.3	0.21	0.33
Total Assets	193.44	110.9	89.4	123.02	38.48
Accounts Payable	3.91	3.41	1.81	2.86	2.85
Accrued Expenses	5.53	6.81	3.71	3.52	3.81
Current Portion of Long-Term Debt	-	-	-	7	5.83
Current Portion of Leases	0.31	0.29	0.31	0.03	0.12
Other Current Liabilities	-	-	-	-	0.11
Total Current Liabilities	9.75	10.51	5.82	13.4	12.72
Long-Term Debt	-	-	-	2.15	8.65
Long-Term Leases	0.45	0.75	1.03	0	0.02
Other Long-Term Liabilities	-	-	-	0	-
Total Long-Term Liabilities	0.45	0.75	1.03	2.16	8.68
Total Liabilities	10.2	11.26	6.86	15.56	21.4
Common Stock	0.13	0.09	0.07	0.06	0.03
Additional Paid-in Capital	512.77	386.53	321.64	317.59	197.96
Accumulated Other Comprehensive Income	0.15	0.06	-0.03	-0.12	-
Retained Earnings	-329.8	-287.05	-239.13	-210.07	-180.92
Shareholders' Equity	183.24	99.64	82.55	107.46	17.08
Total Liabilities & Equity	193.44	110.9	89.4	123.02	38.48
Total Debt	0.75	1.03	1.34	9.18	14.63
Net Cash (Debt)	187.51	106.59	81.63	111.33	22.2
Net Cash Growth	75.91%	30.57%	-26.68%	401.47%	-27.89%
Net Cash Per Share	1.39	1.04	0.82	1.73	0.97
Book Value	183.24	99.64	82.55	107.46	17.08
Book Value Per Share	1.36	0.98	0.83	1.66	0.75
Tangible Book Value	183.24	99.64	82.55	107.46	17.08
Tangible Book Value Per Share	1.36	0.98	0.83	1.66	0.75

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q